| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hydroxycinnamic acid compounds (p-coumaric, caffeic acid (CA), ferulic acid) occur most frequently as simple esters with hydroxy carboxylic acids or glucose, while the hydroxybenzoic acid compounds (p-hydroxybenzoic, gallic acid, ellagic acid) are present mainly in the form of glucosides. https://www.sciencedirect.com/topics/chemistry/hydroxycinnamic-acid Hydroxycinnamic acids (HCAs) are plant-derived phenolic acids (including caffeic, ferulic, p-coumaric, and sinapic acids) with documented antioxidant, anti-inflammatory (NF-κB↓), and context-dependent anticancer effects in cellular and preclinical models. Mechanistic themes include activation of the Nrf2/ARE antioxidant response, suppression of pro-inflammatory and survival pathways (such as NF-κB and PI3K/AKT), modulation of MAPK signaling, and downstream effects on cell-cycle, apoptosis, invasion, and angiogenesis. Oral exposure is influenced by rapid metabolism (phase II conjugates) and food matrix effects, which affects systemic bioavailability and translational relevance. Biological effects vary by specific hydroxycinnamic derivative and its conjugated/esterified form. (Caffeic acid ≠ ferulic acid ≠ sinapic acid) -Ferulic acid and p‐coumaric acid are naturally occurring hydroxycinnamic acids found in many plant-based foods (such as whole grains, fruits, and vegetables) CA showed pro-oxidant potential due to its ability to interact with metals like copper, inducing lipid peroxidation and causing DNA damage within tumor cells through either oxidation or covalent adduct formation. Summary: -HCAs are classically antioxidant -Such as caffeic acid, ferulic acid, and sinapic acid (SA) -May increase sensitivity to chemotherapy -Bioavailability is problem. Formulation strategies (e.g., liposomal or encapsulated forms) are investigated to improve systemic exposure. -Propolis has caffeic acid (Caffeic acid (0.639–4.172 mg/g propolis) -SA at higher concentrations may acts as a potent pro-oxidant agent -SA may act in collaboration with other chemotherapeutic agents to improve treatment sensitivity. -Co-administration of caffeic acid or CAPE with other anti-tumor compounds (e.g., gallic acid) has shown additive or synergistic effects in selected models -Combination of caffeic acid and endogenous copper ions can result in oxidative damage -Ferulic Acid (abundant in whole grains,popcorn): upregulate apoptotic protein and downregulate anti-apoptotic protein.upregulating (BAX), (p53), (CYCS) and downregulating (Bcl-2), Major Hydroxycinnamic Acids and Their Main Mechanisms
Practical grouping: For a class-level Hydroxycinnamic Acid entry, the four core free HCAs are caffeic acid, ferulic acid, p-coumaric acid, and sinapic acid. Chlorogenic acid, rosmarinic acid, and CAPE are chemically related HCA derivatives but have sufficiently distinct pharmacokinetics and biological activity that they are often better maintained as separate database products. Hydroxycinnamic acids — HCAs are a family of plant-derived phenolic acids characterized by a C6-C3 cinnamic-acid backbone bearing one or more hydroxyl/methoxy substituents. Major dietary HCAs include caffeic acid, ferulic acid, p-coumaric acid, and sinapic acid; chlorogenic acids and related esters are important dietary conjugates. HCAs are classified as non-flavonoid polyphenolic phenolic acids and occur widely in coffee, cereals, fruits, vegetables, herbs, and plant-derived foods. They are not a single pharmacologically uniform agent: caffeic acid, ferulic acid, p-coumaric acid, and sinapic acid can differ substantially in potency, redox behavior, metabolism, and molecular targets. Anticancer activity remains predominantly preclinical and should generally be attributed to the specific HCA rather than generalized to the entire class. Primary mechanisms (ranked):
Bioavailability / PK relevance: HCAs are absorbed from the gastrointestinal tract, but the parent aglycones undergo substantial intestinal, hepatic and microbiome metabolism, particularly glucuronidation, sulfation, methylation and hydrogenation. Circulating exposure therefore consists substantially of conjugated and microbial metabolites rather than unchanged parent compound. Food matrix, esterification and site of intestinal release materially alter exposure. Pharmacokinetic reviews indicate that systemic parent-HCA concentrations after dietary intake are generally in the submicromolar-to-low-micromolar range, with one recent systematic assessment reporting maximal blood concentrations around 0.4 µM for cinnamic-acid derivatives such as caffeic/ferulic acid in the datasets examined. Formulation approaches including nanoparticles and encapsulation are being investigated to increase exposure. In-vitro vs systemic exposure relevance: Many reported direct anticancer effects use tens to hundreds of micromolar HCA concentrations. For example, ferulic acid produced IC50 values of approximately 300 µM in PC-3 and 500 µM in LNCaP prostate cancer cells. These concentrations greatly exceed typical circulating concentrations attainable from ordinary dietary exposure. Consequently, direct tumor-cell cytotoxicity demonstrated at high in-vitro concentrations should not be interpreted as evidence that dietary HCAs achieve equivalent systemic anticancer exposure. Metabolites, local gastrointestinal exposure, chronic signaling effects and specialized formulations may have different pharmacological relevance. Clinical evidence status: Preclinical for cancer treatment. There is substantial cell-culture evidence and some animal-tumor evidence for individual HCAs, especially ferulic and caffeic acids, but no established HCA-class anticancer therapy and no convincing randomized human evidence demonstrating treatment of established cancer with isolated HCAs. Human studies more commonly concern dietary exposure, cardiovascular/metabolic effects, pharmacokinetics, skin photoprotection or complex HCA-containing foods/extracts. HCAs should therefore be classified as experimental/preclinical anticancer agents rather than clinical adjuncts. Hydroxycinnamic Acid Cancer Mechanisms
TSF: P: 0–30 min R: 30 min–3 hr G: >3 hr Alzheimer’s disease: Hydroxycinnamic acids have preclinical neuroprotective relevance, particularly caffeic and ferulic acids. Reported mechanisms include suppression of Aβ-associated oxidative stress and neuroinflammation, enhancement of endogenous antioxidant defenses, modulation of CREB/neurotrophic signaling, and possible effects on amyloid- and tau-associated pathology. Evidence is primarily cellular and animal-based; convincing clinical evidence that isolated HCAs prevent or treat Alzheimer’s disease is lacking. Rapid metabolism, low parent-compound systemic exposure and uncertain brain exposure remain important translational constraints. Hydroxycinnamic Acids in Alzheimer’s Disease
|
| Source: |
| Type: |
| Vimentin, a major constituent of the intermediate filament family of proteins, is ubiquitously expressed in normal mesenchymal cells and is known to maintain cellular integrity and provide resistance against stress. Vimentin is overexpressed in various epithelial cancers, including prostate cancer, gastrointestinal tumors, tumors of the central nervous system, breast cancer, malignant melanoma, and lung cancer. Vimentin’s overexpression in cancer correlates well with accelerated tumor growth, invasion, and poor prognosis; however, the role of vimentin in cancer progression remains obscure. In many epithelial-derived tumors (carcinomas), elevated Vimentin expression is often observed in cancer cells that have undergone EMT. This upregulation is characteristic of a shift toward a mesenchymal state, which is associated with reduced cell–cell adhesion and increased motility. Vimentin expression is also noted in the tumor stroma, reflecting the presence and activation of mesenchymal cells such as cancer-associated fibroblasts (CAFs). This dual expression can contribute to the remodeling of the tumor microenvironment. The degree of Vimentin expression may vary depending on the tumor type, grade, and stage. More aggressive and advanced tumors tend to show higher levels of Vimentin expression. High Vimentin expression has been correlated with poor clinical outcomes in several cancers, including breast, colorectal, prostate, and lung cancers. Elevated Vimentin levels are typically associated with higher tumor grade, increased invasiveness, enhanced metastatic potential, and a greater risk of recurrence. As a component of the EMT signature, high Vimentin expression can serve as an indicator of a more aggressive tumor phenotype and is often associated with reduced overall survival. - vimentin up-regulation is often used as a marker of EMT in cancer |
| 1643- | HCAs, | Mechanisms involved in the anticancer effects of sinapic acid |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:95 Target#:336 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid